Skip to main content
NYSE:BVS

Bioventus Competitors

$15.85
-0.06 (-0.38 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.67
$16.26
50-Day Range
$13.75
$16.31
52-Week Range
$10.74
$19.51
Volume41,800 shs
Average Volume235,802 shs
Market Capitalization$900.68 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Bioventus (NYSE:BVS) Vs. SEMR, NAPA, TDUP, PLBY, DSGN, and TBA

Should you be buying BVS stock or one of its competitors? Companies in the industry of "--" are considered alternatives and competitors to Bioventus, including SEMrush (SEMR), The Duckhorn Portfolio (NAPA), ThredUp (TDUP), PLBY Group (PLBY), Design Therapeutics (DSGN), and Thoma Bravo Advantage (TBA).

SEMrush (NASDAQ:SEMR) and Bioventus (NYSE:BVS) are both -- companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares SEMrush and Bioventus' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SEMrushN/AN/AN/AN/AN/A
BioventusN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SEMrush and Bioventus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SEMrush03302.50
Bioventus00403.00

SEMrush presently has a consensus price target of $20.0833, suggesting a potential upside of 10.23%. Bioventus has a consensus price target of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than SEMrush.

Profitability

This table compares SEMrush and Bioventus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SEMrushN/AN/AN/A
BioventusN/AN/AN/A

Summary

Bioventus beats SEMrush on 3 of the 3 factors compared between the two stocks.

The Duckhorn Portfolio (NYSE:NAPA) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares The Duckhorn Portfolio and Bioventus' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Duckhorn PortfolioN/AN/AN/AN/AN/A
BioventusN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for The Duckhorn Portfolio and Bioventus, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Duckhorn Portfolio02702.78
Bioventus00403.00

The Duckhorn Portfolio presently has a consensus target price of $20.7778, suggesting a potential upside of 22.22%. Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than The Duckhorn Portfolio.

Profitability

This table compares The Duckhorn Portfolio and Bioventus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Duckhorn PortfolioN/AN/AN/A
BioventusN/AN/AN/A

Summary

Bioventus beats The Duckhorn Portfolio on 2 of the 3 factors compared between the two stocks.

ThredUp (NASDAQ:TDUP) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares ThredUp and Bioventus' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ThredUpN/AN/AN/AN/AN/A
BioventusN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for ThredUp and Bioventus, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ThredUp01702.88
Bioventus00403.00

ThredUp presently has a consensus target price of $20.8571, suggesting a potential upside of 14.79%. Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than ThredUp.

Profitability

This table compares ThredUp and Bioventus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ThredUpN/AN/AN/A
BioventusN/AN/AN/A

Summary

Bioventus beats ThredUp on 2 of the 3 factors compared between the two stocks.

PLBY Group (NASDAQ:PLBY) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares PLBY Group and Bioventus' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PLBY GroupN/AN/AN/AN/AN/A
BioventusN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for PLBY Group and Bioventus, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PLBY Group00303.00
Bioventus00403.00

PLBY Group presently has a consensus target price of $45.6667, suggesting a potential downside of 2.67%. Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' higher probable upside, analysts plainly believe Bioventus is more favorable than PLBY Group.

Profitability

This table compares PLBY Group and Bioventus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PLBY GroupN/AN/AN/A
BioventusN/AN/AN/A

Summary

Bioventus beats PLBY Group on 2 of the 2 factors compared between the two stocks.

Design Therapeutics (NASDAQ:DSGN) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Design Therapeutics and Bioventus' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Design TherapeuticsN/AN/AN/AN/AN/A
BioventusN/AN/AN/AN/AN/A

Profitability

This table compares Design Therapeutics and Bioventus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Design TherapeuticsN/AN/AN/A
BioventusN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Design Therapeutics and Bioventus, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Design Therapeutics01202.67
Bioventus00403.00

Design Therapeutics presently has a consensus target price of $35.3333, suggesting a potential upside of 53.69%. Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Design Therapeutics' higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Bioventus.

Summary

Bioventus beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.

Thoma Bravo Advantage (NYSE:TBA) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Valuation & Earnings

This table compares Thoma Bravo Advantage and Bioventus' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thoma Bravo AdvantageN/AN/AN/AN/AN/A
BioventusN/AN/AN/AN/AN/A

Profitability

This table compares Thoma Bravo Advantage and Bioventus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thoma Bravo AdvantageN/AN/AN/A
BioventusN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Thoma Bravo Advantage and Bioventus, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thoma Bravo Advantage0000N/A
Bioventus00403.00

Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' higher probable upside, analysts clearly believe Bioventus is more favorable than Thoma Bravo Advantage.

Summary

Bioventus beats Thoma Bravo Advantage on 2 of the 2 factors compared between the two stocks.


Bioventus Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SEMR
SEMrush
1.5$18.22-5.3%$2.46 billionN/A0.00
NAPA
The Duckhorn Portfolio
1.4$17.00-3.5%$1.96 billionN/A0.00
TDUP
ThredUp
1.6$18.17-1.8%$1.65 billionN/A0.00
PLBY Group logo
PLBY
PLBY Group
1.1$46.92-13.9%$1.59 billionN/A0.00Gap Up
DSGN
Design Therapeutics
1.3$22.99-3.0%$1.28 billionN/A0.00
TBA
Thoma Bravo Advantage
0.0$10.24-1.0%$1.05 billionN/A0.00
Apria logo
APR
Apria
1.4$29.04-2.4%$1.02 billionN/A0.00Analyst Revision
FTCI
FTC Solar
0.3$8.38-1.2%$712.80 millionN/A0.00Gap Up
IKNA
Ikena Oncology
1.7$18.33-7.9%$634.00 millionN/A0.00Analyst Revision
CCV
Churchill Capital Corp V
0.0$9.91-0.4%$619.38 millionN/A0.00
Adagene logo
ADAG
Adagene
1.5$12.70-1.2%$552.68 millionN/A0.00
CTOS
Custom Truck One Source
1.0$9.57-4.8%$469.26 millionN/A0.00Earnings Announcement
Analyst Revision
FWAA
Fifth Wall Acquisition Corp. I
0.0$10.34-0.1%$397.66 millionN/A0.00
SVFC
SVF Investment Corp. 3
0.3$10.00-0.3%$359.60 millionN/A0.00
LVTX
Lava Therapeutics B.V.
1.7$12.93-7.9%$327.80 millionN/A0.00
UTME
United Time Technology
0.0$33.02-4.5%$272.97 millionN/A0.00Quiet Period Expiration
Gap Up
SVFB
SVF Investment Corp. 2
0.3$10.00-0.4%$257 millionN/A0.00High Trading Volume
VHAQ
Viveon Health Acquisition
0.0$9.88-0.4%$248.54 millionN/A0.00
HCAQ
HealthCor Catalio Acquisition
0.0$9.85-0.3%$203.90 millionN/A0.00
RACB
Research Alliance Corp. II
0.0$10.81-0.3%$180.64 millionN/A0.00
WNW
Wunong Net Technology
0.0$6.97-10.9%$174.25 millionN/A0.00Gap Up
LBPS
4D pharma
1.7$10.56-0.1%$173.53 millionN/A0.00Upcoming Earnings
ARYD
ARYA Sciences Acquisition Corp IV
0.0$10.25-1.8%$171.28 millionN/A0.00
ABGI
ABG Acquisition Corp. I
0.0$9.88-0.2%$166.35 millionN/A0.00
Biophytis logo
BPTS
Biophytis
0.0$12.70-0.0%$143.68 millionN/A0.00Gap Up
Vivos Therapeutics logo
VVOS
Vivos Therapeutics
1.2$5.97-0.8%$136.19 millionN/A0.00
MRAC
Marquee Raine Acquisition
0.0$9.86-0.3%$108.47 millionN/A0.00
EEIQ
Elite Education Group International
0.0$5.03-2.0%$44.26 millionN/A0.00
Presidio Property Trust logo
SQFT
Presidio Property Trust
0.3$3.05-4.6%$29.00 millionN/A0.00Gap Up
IGNY
Ignyte Acquisition
0.0$9.86-0.1%$19.13 millionN/A0.00
AFAQU
AF Acquisition
0.0$9.95-0.5%$0.00N/A0.00
ANEB
Anebulo Pharmaceuticals
0.0$7.03-0.4%$0.00N/A0.00Gap Down
ANZUU
Anzu Special Acquisition Corp I
0.0$9.98-0.2%$0.00N/A0.00
ATSPU
Archimedes Tech SPAC Partners
0.0$9.96-0.2%$0.00N/A0.00
ARRWU
Arrowroot Acquisition
0.0$9.99-0.0%$0.00N/A0.00
ARTAU
Artisan Acquisition Corp. Units
0.0$9.96-0.8%$0.00N/A0.00High Trading Volume
AUUD
Auddia
0.0$2.47-2.0%$0.00N/A0.00Gap Up
BRIVU
B. Riley Principal 250 Merger Corp. Units
0.0$10.00-0.1%$0.00N/A0.00
BSA
BrightSphere Investment Group
0.0$25.22-0.1%$0.00N/A0.00High Trading Volume
CPZ
Calamos Long/Short Equity & Dynamic Income Term Trust
0.0$20.40-0.2%$0.00N/A0.00
CMLTU
CM Life Sciences III
0.0$10.55-0.3%$0.00N/A0.00High Trading Volume
Quiet Period Expiration
Gap Up
CRZNU
Corazon Capital V838 Monoceros
0.0$10.00-0.2%$0.00N/A0.00
DKDCU
Data Knights Acquisition Corp. Unit
0.0$10.10-0.1%$0.00N/A0.00
DCRCU
Decarbonization Plus Acquisition Corp III
0.0$9.95-0.1%$0.00N/A0.00
DBGI
Digital Brands Group
0.0$3.40-21.8%$0.00N/A0.00High Trading Volume
DLY
DoubleLine Yield Opportunities Fund
0.0$19.77-0.6%$0.00N/A0.00
EBACU
European Biotech Acquisition
0.0$10.00-0.5%$0.00N/A0.00
EVOJ
Evo Acquisition
0.3$9.73-0.4%$0.00N/A0.00
FRSGU
First Reserve Sustainable Growth
0.0$9.98-0.1%$0.00N/A0.00
FMIVU
Forum Merger IV
0.0$9.98-0.2%$0.00N/A0.00
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.